CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:(18)F-fluorodeoxyglucose positron emission tomography-compute tomography parameters for predicting the prognosis and toxicity in children and young adults with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
(18)F-fluorodeoxyglucose positron emission tomography-compute tomography parameters for predicting the prognosis and toxicity in children and young adults with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
aaIPI 和 TMTV 是 PFS 的独立危险因素,ECOG 评分和 TMTV 对 OS 具有独立预后价值。
嵌合抗原受体(CAR)T 细胞疗法已证实可有效治疗复发/难治性大 B 细胞淋巴瘤(LBCL)。有必要及早识别预后不良且可能发生重度副作用的患者。本研究评估 ¹⁸F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(¹⁸F-FDG PET/CT)参数预测儿童和青年成人 LBCL 患者 CAR-T 治疗预后及毒性的价值。
本回顾性队列研究纳入年龄 <30 岁的 LBCL 患者;其在 CAR-T 输注前 1 个月内于首都医科大学附属北京友谊医院或北京高博博仁医院接受 ¹⁸F-FDG PET/CT 检查。记录 PET/CT 代谢参数,包括最大标准摄取值(SUVmax)、总代谢肿瘤体积(TMTV)和总病灶糖酵解(TLG),并收集临床特征和实验室指标。主要终点为 Kaplan-Meier 法及 log-rank 检验估计的无进展生存期(PFS)和总生存期(OS)。此外,评估代谢及临床参数与重度毒性(包括 CRS 和 ICANS)的关系。
共纳入 45 例患者,中位随访 13.9 个月。年龄校正国际预后指数(aaIPI)为 2–3(P = 0.014)及 TMTV >101.4 mL(P = 0.026)的患者 PFS 较短。ECOG 体能状态评分 2–3(P = 0.015)及 TMTV >101.4 mL(P = 0.011)与较短 OS 相关。乳酸脱氢酶(LDH)高于正常上限(UNL)(P = 0.030)和 TMTV >101.4 mL(P = 0.042)与 2–4 级 CRS 相关;C 反应蛋白(CRP)高于 UNL(P = 0.014)与 2–4 级 ICANS 相关。
aaIPI 和 TMTV 是 PFS 的独立危险因素;ECOG 评分和 TMTV 对 OS 具有独立预后价值。LDH 和 TMTV 较高与 2–4 级 CRS 相关,CRP 较高与更重度 ICANS 相关。因此,综合 ¹⁸F-FDG PET/CT 代谢参数与临床实验室指标,有助于管理接受 CAR-T 治疗的儿童和青年成人 B 细胞淋巴瘤患者。
Chimeric antigen receptor (CAR) T-cell therapy has been proven to be an effective choice for patients with relapsed or refractory large B-cell lymphoma (LBCL). Early identification of patients who may have a poor prognosis and develop severe side effects is necessary. In this study, we aimed to assess the value of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET/CT) parameters in predicting the prognosis and toxicity of CAR T therapy for children and young adults with LBCL.
This retrospective cohort study included patients with LBCL under 30 years of age who underwent 18 F-FDG PET/CT at Beijing Friendship Hospital of Capital Medical University and Beijing GoBroad Boren Hospital before CAR T-cell infusion within 1 month. 18 F-FDG PET/CT metabolic parameters including maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) were recorded. Clinical characteristics and laboratory indicators were also collected. The main endpoints were progression-free survival (PFS) and overall survival (OS) as estimated by the Kaplan-Meier method and log-rank test. We also assessed the relationship between these metabolic and clinical parameters and severe toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Forty-five patients were recruited. The median duration of the follow-up period was 13.9 months. Patients with an age-adjusted international prognostic index (aaIPI) 2-3 (P=0.014) and TMTV >101.4 mL (P=0.026) had a shorter PFS. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 2-3 (P=0.015) and TMTV >101.4 mL (P=0.011) had a shorter OS. Lactate dehydrogenase (LDH) > upper normal limit (UNL) (P=0.030) and TMTV >101.4 mL (P=0.042) were associated with grade 2-4 CRS, and C-reactive protein (CRP) > UNL (P=0.014) was associated with grade 2-4 ICANS.
aaIPI and TMTV were independent risk factors for PFS, and ECOG score and TMTV had independent prognostic value for OS. Higher LDH and TMTV were associated with grade 2-4 CRS, and higher CRP was associated with more severe ICANS. Thus, integrating these metabolic parameters of 18 F-FDG PET/CT and clinical-laboratory indicators can be valuable for managing children and young adults with B-cell lymphoma who have received CAR T-cell therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。